Maletira G Machayya, MD in Valley City, ND - Surgery

Maletira G Machayya, MD is a Surgery physician based in Valley City, North Dakota. Maletira G Machayya is licensed to practice in North Dakota (license number 3284) and his current practice location is 520 Chautauqua Blvd, Valley City, North Dakota. He can be reached at his office (for appointments etc.) via phone at (701) 845-6000.

NPI number for Maletira G Machayya is 1417974023 and his current mailing address is 520 Chautauqua Blvd, Valley City, North Dakota. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1417974023.

Contact Information

	Maletira G Machayya, MD
	520 Chautauqua Blvd, Valley City, ND 58072-3145
	(701) 845-6000
	(701) 845-6150

Physician's Profile

Full Name	Maletira G Machayya
Gender	Male
Speciality	Surgery
Location	520 Chautauqua Blvd, Valley City, North Dakota
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1417974023
Provider Enumeration Date: 07/17/2006
Last Update Date: 09/11/2008

Medical Identifiers

Medical identifiers for Maletira G Machayya such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1417974023	NPI	-	NPPES
12599	Medicaid	ND
518395200	Medicaid	MN

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208600000X	Surgery	3284 (North Dakota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Maletira G Machayya is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Maletira G Machayya, MD 520 Chautauqua Blvd, Valley City, ND 58072-3145 Ph: (701) 845-6000	Maletira G Machayya, MD 520 Chautauqua Blvd, Valley City, ND 58072-3145 Ph: (701) 845-6000

News Archive

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Resveratrol concentration impacts cancer risk mitigation: Study

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

New study may pave way for more effective treatment for deadly childhood cancer

A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.

Study maps potential link between oil and gas production and childhood leukemia risk

A pilot study of childhood leukemia patients living near Colorado's oil and gas drilling sites recently led to an American Cancer Society grant award for CU Cancer Center member Lisa McKenzie PhD, MPH.

Meditrina licensor AstraZeneca granted US allowance of patent for endometriosis treatment

Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.

Maletira G Machayya, MD - Surgery in Valley City, ND